{"classes":[{"categories":[{"measurements":[{"comment":"A confidence interval cannot be estimated at this time-point because none of the participants had progressed.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"1.00"}]}],"title":"16 weeks"},{"categories":[{"measurements":[{"comment":"A confidence interval cannot be estimated at this time-point because none of the participants had progressed.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"1.00"}]}],"title":"32 weeks"},{"categories":[{"measurements":[{"comment":"A confidence interval cannot be estimated at this time-point because none of the participants had progressed.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"1.00"}]}],"title":"48 weeks"},{"categories":[{"measurements":[{"comment":"A confidence interval cannot be estimated at this time-point because none of the participants had progressed.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"1.00"}]}],"title":"64 weeks"},{"categories":[{"measurements":[{"comment":"A confidence interval cannot be estimated at this time-point because none of the participants had progressed.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"1.00"}]}],"title":"80 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.84","upperLimit":"1.00","value":"0.98"}]}],"title":"96 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.82","upperLimit":"0.99","value":"0.95"}]}],"title":"112 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.82","upperLimit":"0.99","value":"0.95"}]}],"title":"128 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.82","upperLimit":"0.99","value":"0.95"}]}],"title":"144 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.79","upperLimit":"0.98","value":"0.93"}]}],"title":"160 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.79","upperLimit":"0.98","value":"0.93"}]}],"title":"176 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.79","upperLimit":"0.98","value":"0.93"}]}],"title":"192 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.66","upperLimit":"0.95","value":"0.87"}]}],"title":"208 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.34","upperLimit":"0.91","value":"0.72"}]}],"title":"224 weeks"},{"categories":[{"measurements":[{"comment":"No additional progression was experienced within population at week 240.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"240 weeks"},{"categories":[{"measurements":[{"comment":"No additional progression was experienced within population at week 256.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"256 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"description":"Duration of spleen volume reduction is defined as the time from the first occurrence of a \\>=35% reduction from baseline in spleen volume until the date of the first documented progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy","id":"OG000","title":"Ruxolitinib"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS) comprises all participants to whom study treatment had been assigned by randomization. Duration of the reduction in spleen volume was pre-specified in the protocol to be analyzed for the ruxolitinib arm only considering the study design which allowed crossover for the BAT arm beginning at Week 32.","reportingStatus":"POSTED","timeFrame":"256 Weeks","title":"Duration of Reduction in Spleen Volume","type":"SECONDARY","unitOfMeasure":"probability"}